v3.25.4
Segment Information - Schedule of Segment Expenses and Segment Operating Loss (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Segment Reporting Information [Line Items]    
Total research and development expense $ 148,024 $ 144,101
Total general and administrative 32,863 48,849
Stock based compensation 20,720 51,767
Net loss (158,349) (168,385)
Operating Segment    
Segment Reporting Information [Line Items]    
Total research and development expense [1] 137,578 120,029
Total general and administrative [2] 22,589 21,154
Stock based compensation 20,720 51,767
Other segment items [3] (22,538) (24,564)
Net loss (158,349) (168,386)
COVID-19 external costs | Operating Segment    
Segment Reporting Information [Line Items]    
Total research and development expense [1],[4] 1,490 60,734
HCV external costs | Operating Segment    
Segment Reporting Information [Line Items]    
Total research and development expense [1],[4] 109,574 34,106
Early stage discovery external costs | Operating Segment    
Segment Reporting Information [Line Items]    
Total research and development expense [1],[4] 3,800 943
Compensation and related expenses | Operating Segment    
Segment Reporting Information [Line Items]    
Total research and development expense [1] 18,753 20,448
Total general and administrative [2] 9,094 9,279
Consulting and professional fees | Operating Segment    
Segment Reporting Information [Line Items]    
Total research and development expense [1] 2,183 1,959
Total general and administrative [2] 12,004 10,031
Other research and development expenses | Operating Segment    
Segment Reporting Information [Line Items]    
Total research and development expense [1] 1,778 1,839
Other general and administrative | Operating Segment    
Segment Reporting Information [Line Items]    
Total general and administrative [2] $ 1,491 $ 1,844
[1] Research and development expense for the years ended December 31, 2025 and 2024 excludes stock based compensation of $10,446 and $24,072, respectively.
[2] General and administrative expense for the years ended December 31, 2025 and 2024 excludes stock based compensation of $10,274 and $27,695, respectively.
[3] Other segment items include Interest income and other, net and income tax benefit (expense).
[4] External costs consist primarily of discovery, preclinical, clinical and manufacturing related activities.